2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2807

Skin and Muscle Sodium Concentrations in Patients with Systemic Lupus Erythematosus: A Proof of Concept Study
Abstract Number: 210

Skin Events with Febuxostat in Gout Patients and Previous Skin Reactions to Allopurinol. a Retrospective Review
Abstract Number: 1816

SLE and Uctd in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 1836

SLE Bone Marrow Contains Factors That Promote Type I Interferon Activation
Abstract Number: 2876

SLE Serum Impairs NO Production in Huvecs through Induction of eNOS Uncoupling
Abstract Number: 2872

SLE Subjects Express High Levels of Intracellular Interferon-β That Acts in an Autocrine Fashion to Promote Survival of Transitional Stage B Cells
Abstract Number: 410

Sleep and Its Relationship to Pain and Disease Activity in Turkish Children and Adolescent with Juvenile Idiopathic Arthritis
Abstract Number: 3251

Sleep and Physical Activity: A Nationwide Survey Among People with Rheumatic Disease in Ireland
Abstract Number: 2403

Sleep Disruption in Children with Chronic Pain
Abstract Number: 1536

Sleep Disturbance in Patients with Rheumatoid Arthritis – a Cross-Section Study
Abstract Number: 2761

Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors
Abstract Number: 1759

Sleep Disturbance Is Associated with Worsening Patient-Reported Outcomes over Two Years in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1532

Sleep Hygiene Practices and Associations with Patient-Reported Outcomes in Rheumatoid Arthritis
Abstract Number: 2337

Sleep Quality, Disturbances and Physical Activity: A Nationwide Survey Among Health Professionals on Their Engagement with Irish People Who Have Rheumatic Disease
Abstract Number: 42

Small Fibre Neuropathy Biopsies (SFN) in Primary Fibromyalgia Revealed Predominant Association with Metabolic Syndrome (in addition to other known treatable causes of SFN) but No Clear Distinction Related to Biopsy Results

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].